ReaGene Biosciences announces filing of PCT for its proprietary 3D printing platform for Drug Discovery and Development titled:

“Integrated 3D bioprinted human disease in a dish model to simultaneously study drug discovery and development parameters'”

ReaGene Biosciences announces filing of PCT for its proprietary 3D printing platform for Drug Discovery and Development titled – “Integrated 3D bioprinted human disease in a dish model to simultaneously study drug discovery and development parameters’”

ReaGene has been working on developing a unique 3D bioprinted alternatives to traditional Animal testing or single cell/tissue and 2D studies. The platform comprises precise printing of a battery of human cells that are engineered to replicate the morphological, physiological as well as the disease state encountered by the drug in the patients. 

By creating a mix of multi-layered 3 D printed cell systems and customized niche assays with specific conditions, Reagene is making it possible to both reduce the multiplicity of in vitro assays as well as increase the throughput of compounds tested.

The novel platform can be of tremendous value in simultaneously assessing the efficacy, toxicity as well as other ADME parameters of candidate drugs at the preclinical stage to provide deep insights into the decision-making process,  Go/ No-Go decisions and Candidate selection for further development. The platform can be applied to most disease conditions. The Company plans to specially apply this platform to diseases that have poor animal model to human studies translation such as cancer and sepsis and rare diseases that have no validated animal models.